Clinical and genetic profile of Familial Parkinson´s disease in Cali – Colombia
Objective: This study aims to describe the genetic and clinical profile of 32 subjects with familial PD using NGS genetic panel and eMotion software system…H1/H2 MAPT Haplotype and Parkinson’s Disease in an Ashkenazi Jewish Cohort
Objective: To study the Microtubule-Associated Protein Tau (MAPT) H1/H2 haplotype contribution to clinical manifestation of Parkinson’s disease (PD) in an Ashkenazi Jewish (AJ) cohort, focusing…Rotenone exposure is associated with mitochondrial DNA (mtDNA) damage in humans
Objective: To determine if mtDNA damage can serve as a biomarker of prior pesticide exposure. Background: Mitochondrial dysfunction is a hallmark of PD, and exposure…Compartment-specific blockade of dopamine uptake in nigrostriatal pathway reveals role for nigral dopamine function in movement frequency in open-field
Objective: Inhibition of tyrosine hydroxylase activity in the substantia nigra (SN) produces a significant reduction in locomotor motor activity commensurate with decreased dopamine (DA) content…Identifying de novo Parkinson’s disease with optical coherence tomography of the retina: A machine learning classification approach
Objective: To identify and classify de novo Parkinson’s disease patients compared to healthy controls (HC). Background: PD patients experience visual symptoms and retinal degeneration. Studies…Nucleus basalis of Meynert free-water distinguishes and predicts cognitive impairment and longitudinally correlates with cognitive changes in early Parkinson’s disease
Objective: To explore diffusion-based MRI assessments of the nucleus basalis of Meynert (nbM) as a neuroimaging biomarker of cognitive abilities and longitudinal cognitive changes in…Quantitative Susceptibility Mapping may help distinguish patients with Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy with predominant parkinsonism
Objective: The purpose of this study was to examine quantitative susceptibility mapping (QSM) changes in PD and multiple system atrophy with predominant parkinsonism (MSA-P) and…Dopaminergic denervation in de-novo Parkinson’s disease. Does functional somatotopy plays a role?
Objective: To clarify how dopaminergic denervation occurs along the dorsoventral axis of the posterior putamen in the earliest stages of PD. Background: Dopamine loss in…FDG PET and MIBG scintigraphy in the differential diagnosis of parkinsonism: a head-to-head comparison
Objective: To compare the performance of [18F]fluorodeoxyglucose (FDG) PET and [123I]metaiodobenzylguanidine (MIBG) scintigraphy in the differential diagnosis of parkinsonism in the same patient sample. Background:…Brain atrophy progression in de novo Parkinson’s disease
Objective: Using deformation-based morphometry (DBM) as a measure of atrophy, the aim of this study was to identify the regions presenting structural brain changes after…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 149
- Next Page »